Action‑able biotech options brief: This report dissects INmune Bio (INMB) vs Altimmune (ALT) for a 45‑day naked‑put play. You’ll get snapshot fundamentals, catalyst calendars, support/resistance maps, IV/skew math, insider & short‑interest heat, plus crash‑probability odds—then a clear verdict on which ticker offers the juicier premium with the safer floor (spoiler: ALT). Perfect for traders who want high‑volatility income without wading through 10‑K’s.